Did a lab of AI 'scientists' design a possible Covid-19 treatment?

The Star

2 days ago

What does a scientist look like?
A bright-eyed intellectual donning a white lab coat and goggles? Often, yes. But these days, they could take on the look of a stack of computer servers softly humming away in an air-conditioned building.
That's what a group of scientists from the San Francisco-based Chan Zuckerberg Biohub and Stanford University aim to do with a 'Virtual Lab' of artificial intelligence scientists tasked with doing original research on a potential treatment for COVID-19.
'You can imagine each researcher having their own team of AI scientist(s) that can be their assistants,' said James Zou, a professor and computer scientist at Stanford University who co-led the study. 'It's quite versatile … I'm super excited that the Virtual Lab could be an accelerator for many types of science.'
The AI scientists held meetings, wrote code, and made (virtual) biological models before proposing a slate of molecules to help treat recent COVID variants. After testing the Virtual Lab's suggestions in the real lab, the scientists found two molecules that might serve as a potential COVID treatment, as they describe in a paper published Tuesday in the journal Nature. While the potential treatment has a long way to go before becoming medicine, the (human) researchers say their model of creating a group of AI scientists could help accelerate discoveries across the scientific world.
Scientific discovery often relies on groups of experts coming together to workshop ideas from different angles to try and solve a problem together. This can produce results that can shift the scientific world – the work that led to the 2024 Nobel Prize in Chemistry involved dozens of scientists in fields from biology to computer science. But access to that depth of connection can be hard to come by, argue Zou and his colleagues.
So Zou wondered if there was a way to imitate those conversations between real-world researchers but with AI. While some individual AI systems already are about as good as humans at answering some scientific questions, few people have experimented with putting those AIs in conversation with each other.
To test the idea, the team decided to create a Virtual Lab of AI scientists and give it a thorny, open-ended problem: creating antibody treatments for recent strains of COVID-19. Antibodies can help treat the disease, but are made less effective every time the virus evolves into a new variant, so quickly developing new antibodies could help keep treatments up to date.
The Virtual Lab was run by an AI Principal Investigator, who after getting the assignment, made a team of AI experts to collaborate with on the task. The human researchers armed the AI experts with software that would help them do their jobs such as a software to model proteins for an AI biologist.
Together, the AI lab held group meetings to come up with ideas, and then individual meetings to accomplish individual tasks. The AI team came up with a path to propose treatments – opting to create nanobodies, the antibody's smaller cousin. The group proposed potential treatments, then wrote code, created computer models to test those treatments and improve on the design of the potential treatment.
'One of the benefits of the virtual lab is that their meetings are much more efficient than our human meetings,' said Zou, noting that the meetings are over in a matter of minutes and several can be run at the same time. 'They can actually run a lot of meetings and run these meetings in parallel so they don't get tired.'
As a testament to this speed, while it took the researchers months to set up the virtual lab, it only took the Virtual Lab two days to propose 92 different candidates of potential COVID-19 treatments. Of these, two seemed particularly promising in attaching themselves to COVID-19 proteins in the lab, meaning they could be potential treatments.
Importantly, while many AI systems provide answers without explaining how they got there, the Virtual Lab had a transcript of all of its conversations. This allowed the human to understand the logic behind the AI scientists' decisions.
'That was very encouraging to us,' said John Pak, a biochemist and staff scientist at the Chan Zuckerberg Biohub who co-led the study. 'As a researcher, you can always be kind of hesitant to incorporate (AI) into your daily routine, but with the virtual lab and the AI agents, it felt pretty natural to interact with.'
Samuel Rodrigues, an AI researcher who was not involved in the study, called the research 'a very exciting advance' over email. Rodrigues, CEO of FutureHouse, a San Francisco-based company building AI to automate scientific research, described the approach of multiple AI scientists as 'very visionary' and 'extremely important' for incorporating AI into science. While he noted that the system would likely have to be tweaked to do other tasks, he argued that was a minor limitation.
'Overall, we are impressed by and are very big fans of this work,' he said.
The scientists agree that to create more informed AI experts, future users could arm them with tools and training to make them better, but argue that the system is already quite versatile.
Even so, they admit that the Virtual Lab has its limits. AI systems can sometimes make up facts based on erroneous or incomplete data, such as when an early version of Google's AI overview suggested putting glue into pizza sauce or eating a rock a day.
To minimise these sorts of gaffes, the team included an AI scientific critic as part of the Virtual Lab to question the assertions of the rest of the group, and often had the lab run several meetings on the same question to see if they arrived at similar conclusions. Ultimately, the Virtual Lab still relied on a human expert who can guide the AI, check its work, and test its assertions in real life.
The researchers also noted that while the nanobodies may be responsive in a petri dish, human bodies are far more complicated, so using these molecules as a treatment would require far more testing before scientists knew whether the nanobodies actually would work in people.
Despite these limitations, both Zou and Pak argue that the Virtual Lab offers a valuable tool for research across fields. 'We're really focused on exploratory research that could – in the hands of others – be useful,' said Pak. 'I'm kind of excited about testing this out with different scientific questions … I'm looking forward to trying it out with other projects that we have going on in the lab.' – The Mercury News/Tribune News Service